Advertisement

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

REGISTER for free or LOG IN to view this content

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Clinical Cardiology

Clinical Pharma

Lipids

Prevention

Coronary

ACS/AMI

CAD Pharma

ESC 2017

Up Next

PCI vs CABG in Patients with Type 1 Diabetes and Multivessel Disease

Presenter: Martin J. Holzmann

August 28, 2017

More slides +

DETermination of the role of OXygen in suspected Acute Myocardial Infarction

Presenter: Robin Hofmann

August 28, 2017

Guidelines for the Management of Acute Myocardial Infarction in Patients presenting with ST-Segment Elevation

Presenter: Borja Ibanez

August 28, 2017

Country